BioNTech SE (BNTX NASDAQ) stock market data APIs
$97.9106
-0.8(-0.8%)
as of May 23, 2025
Try our APIs with
free plan!
BioNTech SE Financial Data Overview
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Prev. Close
97.9106
Open
97.1099
High
98.2724
Low
97.1941
52 wk Range
76.53-131.49
Market Cap
23 722 M
Shares Outstanding
240 M
Revenue
2 746 M
EPS
-1.8208
Beta
1.36
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BioNTech SE data using free add-ons & libraries
Get BioNTech SE Fundamental Data
{
"General": {
"Code": "BNTX",
"Type": "Common Stock",
"Name": "BioNTech SE",
"Exchange": "NASDAQ",
"CurrencyCode": "USD",
"CurrencyName": "US Dollar",
"CurrencySymbol": "$",
"CountryName": "USA",
"CountryISO": "US",
"OpenFigi": "BBG00Q70B3V1",
"ISIN": null,
"CUSIP": null,
"CIK": "0001776985",
"EmployerIdNumber": null,
"FiscalYearEnd": "December",
"IPODate": "2019-10-10",
"InternationalDomestic": null,
"Sector": "Healthcare",
"Industry": "Biotechnology",
"HomeCategory": "ADR",
"IsDelisted": false,
"Description": "BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell ..."
}
}BioNTech SE Fundamental data includes:
- Net Revenue: 2 746 M
- EBITDA: -1 019 900 032
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-16
- EPS/Forecast: -2.3471
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioNTech SE News
New
BioNTech Strengthens UK Ties with Investment of Up to $1.33 Billion
German vaccine maker BioNTech SE (NASDAQ:BNTX) revealed on May 20 that it intends to boost its presence in the UK with an investment of up to £1 billion ($1.33 billion) over the next decade, focusing...
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
Shares of prominent COVID-19 vaccine-makers Moderna MRNA, Pfizer PFE and BioNTech BNTX rose yesterday after the FDA issued new guidance for COVID-19 vaccine boosters. FDA’s New Requirements for COV...
BioNTech to invest up to $1.34bn in UK R&D
BioNTech has made a grant agreement with the UK government to expand its research and development (R&D) activities for medicines, committing an investment of up to £1bn ($1.34bn) up to 2034. This wi...
The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.
The FDA said Tuesday it will limit future Covid vaccines to older and at-risk Americans. The move buoyed Moderna, BioNTech and Novavax. Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
